You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

NY-ESO-1

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

HLA-A*0201 Positive Cells Present, NY-ESO-1 Positive Tumor Cells Present, Recurrent Myxoid Liposarcoma Trial in Houston

Active, not recruiting
  • HLA-A*0201 Positive Cells Present
  • +3 more
  • Aldesleukin
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Feb 25, 2022

Select Advanced Solid Tumors Trial in Canada, United Kingdom, United States (IMCnyeso)

Terminated
Has Results
  • Select Advanced Solid Tumors
  • Aurora, Colorado
  • +11 more
Mar 9, 2022

Tumors Trial in Worldwide (GSK3845097, Cyclophosphamide, Fludarabine)

Terminated
  • Neoplasms
  • New Haven, Connecticut
  • +20 more
Jul 5, 2023

Tumors Trial in United States (NY-ESO-1(c259)T Cells, Fludarabine, Cyclophosphamide)

Completed
Has Results
  • Neoplasms
  • NY-ESO-1(c259)T Cells
  • +2 more
  • Duarte, California
  • +7 more
Jun 9, 2021

Ovarian Cancer Stage IV, Ovarian Cancer Stage III, Ovarian Cancer Stage 3 Trial in Washington, Hackensack (NY-ESO-1 Peptide

Not yet recruiting
  • Ovarian Cancer Stage IV
  • +2 more
  • Washington, District of Columbia
  • +2 more
Jul 28, 2022

Fallopian Tube Carcinoma, Ovarian Carcinoma, Primary Peritoneal Carcinoma Trial in Buffalo (biological, drug, other)

Completed
  • Fallopian Tube Carcinoma
  • +2 more
  • DEC-205/NY-ESO-1 Fusion Protein CDX-1401
  • +4 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Jul 20, 2021

Tumors Trial in Worldwide (Letetresgene autoleucel (lete-cel, GSK3377794), Fludarabine, Cyclophosphamide)

Active, not recruiting
  • Neoplasms
  • Letetresgene autoleucel (lete-cel, GSK3377794)
  • +2 more
  • Duarte, California
  • +36 more
Oct 28, 2022

Melanoma (Skin), Triple-Negative Breast Cancer, NSCLC Trial (PeptiCRAd-1, Cyclophosphamide, Pembrolizumab)

Not yet recruiting
  • Melanoma (Skin)
  • +2 more
  • (no location specified)
Aug 5, 2022

Melanoma, Meningioma, Breast Cancer Trial run by the NCI (Anti-NY ESO-1 mTCR PBL, Cyclophosphamide, Fludarabine)

Completed
Has Results
  • Melanoma
  • +4 more
  • Anti-NY ESO-1 mTCR PBL
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Mar 1, 2021

Melanoma Trial in New York (DC Vaccine, Montanide Vaccine, Poly-ICLC)

Completed
  • Melanoma
  • DC Vaccine
  • +2 more
  • New York, New York
  • +1 more
Sep 13, 2022

Acute Myeloid Leukemia, Blasts 30 Percent or Less of Bone Marrow Nucleated Cells, Chronic Myelomonocytic Leukemia Trial in

Completed
  • Acute Myeloid Leukemia
  • +5 more
  • DEC-205/NY-ESO-1 Fusion Protein CDX-1401
  • +4 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Oct 4, 2021

NSCLC (NSCLC) Trial in United Kingdom (ChAdOx1-MAGEA3-NYESO, MVA-MAGEA3, Standard of care treatment)

Recruiting
  • Non-small Cell Lung Cancer (NSCLC)
  • ChAdOx1-MAGEA3-NYESO
  • +2 more
  • Birmingham, United Kingdom
  • +7 more
Dec 16, 2021

Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma Trial in Buffalo

Active, not recruiting
  • Recurrent Fallopian Tube Carcinoma
  • +2 more
  • Aldesleukin
  • +4 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Mar 3, 2022

Tumors Trial in Miami, Tampa, Houston (letetresgene autoleucel (GSK3377794), Cyclophosphamide, Fludarabine)

Completed
Has Results
  • Neoplasms
  • letetresgene autoleucel (GSK3377794)
  • +2 more
  • Miami, Florida
  • +2 more
Aug 10, 2021

Prostate Cancer Trial in Frankfurt, Zurich (NY-ESO-1 protein/CpG 7909)

Completed
Has Results
  • Prostate Cancer
  • NY-ESO-1 protein/CpG 7909
  • Frankfurt, Germany
  • +1 more
Jan 7, 2021

Melanoma (Skin) Trial in Tampa (MART-1, NY-ESO-1, gp100:209-217(210M))

Completed
  • Melanoma (Skin)
  • MART-1
  • +5 more
  • Tampa, Florida
    H. Lee Moffitt Cancer Center and Research Institute
Jan 17, 2023

Melanoma Trial in Germany (Lipo-MERIT)

Active, not recruiting
  • Melanoma
  • Lipo-MERIT
  • Frankfurt, Germany
  • +3 more
Jan 5, 2023

Malignant Melanoma Trial in New York (Imiquimod, NY-ESO-1 protein)

Completed
Has Results
  • Malignant Melanoma
  • New York, New York
    NYU Cancer Institute
Sep 28, 2020

Multiple Myeloma, Melanoma, Synovial Sarcoma Trial in Philadelphia (biological, drug, device)

Terminated
  • Multiple Myeloma
  • +3 more
  • NY-ESO-1 redirected autologous T cells with CRISPR edited endogenous TCR and PD-1
  • +3 more
  • Philadelphia, Pennsylvania
    University of Pennsylvania
Oct 9, 2020

Melanoma Trial in Lausanne, Geneva (Melan-A ELA + Montanide, Melan-A ELA + NY-ESO-1b + MAGE-A10 + Montanide, Melan-A -ELA +

Completed
Has Results
  • Melanoma
  • Melan-A ELA + Montanide
  • +4 more
  • Lausanne, Vaud, Switzerland
  • +1 more
Jun 2, 2020

Cutaneous Melanoma, Melanoma, Melanoma of Unknown Primary Trial in United States (DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly

Completed
Has Results
  • Cutaneous Melanoma
  • +11 more
  • DEC-205/NY-ESO-1 Fusion Protein CDX-1401
  • +2 more
  • Chicago, Illinois
  • +6 more
Nov 10, 2021

Esophagus Cancer, Hepatoma, Glioma Trial in Zhengzhou (CAR-T/TCR-T cells immunotherapy)

Unknown status
  • Esophagus Cancer
  • +3 more
  • CAR-T/TCR-T cells immunotherapy
  • Zhengzhou, Henan, China
    Henan Provincial People's Hospital
Feb 3, 2021

Sarcoma, Melanoma, NSCLC Trial in United States (CMB305, G100, Metronomic CPA)

Terminated
  • Sarcoma
  • +3 more
  • CMB305
  • +2 more
  • Santa Monica, California
  • +7 more
Jun 29, 2020

Melanoma Trial in Lausanne (2 vaccine injections in 1 limb, 2 vaccine injections in distinct limbs, 2 "vaccine injections" in

Terminated
Has Results
  • Melanoma
  • 2 vaccine injections in 1 limb
  • +2 more
  • Lausanne, Vaud, Switzerland
    Oncology Department, CHUV
May 26, 2020

Advanced Solid Tumor Trial in Nijmegen (PRECIOUS-01)

Recruiting
  • Advanced Solid Tumor
  • Nijmegen, Gelderland, Netherlands
    Radboudumc
Oct 26, 2022